2026-02-09, 7:59:37 a.m.
EMERYVILLE, Calif. — February 9, 2026 — Leads & Copy — XOMA Royalty Corporation (NASDAQ: XOMA) has successfully completed its tender offer to acquire all outstanding shares of Generation Bio Co. (NASDAQ: GBIO) common stock.
The acquisition was completed for a price of $4.2913 per share in cash, plus one non-tradeable contingent value right.
The tender offer and related withdrawal rights expired on February 6, 2026. Approximately 70%, or 4,722,533 shares, of Generation Bio common stock were validly tendered and not validly withdrawn as of the expiration date. XOMA Royalty irrevocably accepted for payment all shares validly tendered and expects to promptly pay for the shares.
Following the closing of the tender offer, a subsidiary of XOMA Royalty, XRA 7 Corp., merged with Generation Bio. Shares of Generation Bio common stock that had not been tendered were converted into the right to receive the offer price without interest. Generation Bio became a wholly owned subsidiary of XOMA Royalty as a result of the merger.
Trading of Generation Bio common stock on The Nasdaq Stock Market LLC ceased on February 6. XOMA Royalty and Generation Bio intend to delist the shares from Nasdaq and deregister them under the Securities Exchange Act of 1934.
Gibson, Dunn & Crutcher LLP represented XOMA Royalty. TD Cowen served as financial advisor to Generation Bio, and Wilmer Cutler Pickering Hale and Dorr LLP served as legal counsel.
XOMA Royalty acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The seller receives non-dilutive, non-recourse funding to advance their internal drug candidate(s) or for general corporate purposes.
XOMA Royalty has a growing portfolio of assets, which are defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate.
Certain statements in the release are forward-looking, including statements regarding the payment and expected timing of payment of the tender offer, the delisting and deregistration of Generation Bio common stock, the ability of XOMA Royalty to monetize Generation Bio’s delivery platform, and the ability to achieve any dispositions within the disposition period under the CVR Agreement.
Forward-looking statements are not a guarantee of performance, and actual results could differ materially from those anticipated due to certain risks, including the risk that XOMA Royalty does not achieve anticipated net cash after winding down Generation Bio’s operations and concluding remaining activities, and the risk that XOMA Royalty is unable to develop or otherwise enter into dispositions related to the Generation Bio programs.
Other potential risks to XOMA Royalty meeting these expectations are described in more detail in XOMA Royalty’s most recent filing on Form 10-Q and in other filings with the Securities and Exchange Commission.
Any forward-looking statement in this press release represents XOMA Royalty’s beliefs and assumptions only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date.
References to “portfolio” in this press release refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. References to “assets” in this press release refer strictly to milestone and/or royalty rights associated with individual drug products in development.
Source: XOMA Royalty
